Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORGESIC FORTE vs AMRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norgesic Forte is a combination of orphenadrine citrate and aspirin (acetylsalicylic acid). Orphenadrine is a centrally acting muscle relaxant with anticholinergic and antihistaminic properties; it acts via blockade of nicotinic acetylcholine receptors at the neuromuscular junction and centrally as a non-competitive antagonist at NMDA receptors, reducing hypertonicity and spasm. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Relief of discomfort associated with acute painful musculoskeletal conditions,Adjunct to rest, physical therapy, and other measures for the relief of muscle spasm associated with acute painful musculoskeletal conditions
Treatment of spasticity due to multiple sclerosis, spinal cord injury, or other spinal cord disorders
1 tablet orally 3 times daily. Each tablet contains orphenadrine citrate 100 mg and paracetamol 500 mg.
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
Terminal elimination half-life: 4-6 hours; in elderly or hepatic impairment, half-life may be prolonged up to 12 hours, necessitating dose adjustment.
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
Orphenadrine: extensively hepatic, primarily via N-demethylation (CYP2B6, CYP3A4) and hydroxylation; aspirin: rapidly hydrolyzed to salicylic acid by esterases (liver, plasma, erythrocytes), further metabolized by conjugation with glycine (salicyluric acid) and glucuronic acid, and oxidation to gentisic acid.
Hepatic via deamination; primarily metabolized by monoamine oxidase B (MAO-B) to inactive metabolites.
Renal (70% as unchanged drug and conjugates), fecal (20%), biliary (10%)
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
95% bound; primarily to albumin and alpha-1-acid glycoprotein
40–45% bound to serum proteins, primarily albumin
Vd: 1.0 L/kg; indicates extensive tissue distribution ( > total body water, 0.6 L/kg).
5–8 L/kg; suggests extensive tissue distribution, including skeletal muscle
Oral: 80-90% (due to first-pass metabolism); intramuscular: 100%
Oral: 85–95% (extended-release formulation)
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-60 m L/min), reduce frequency to twice daily. No adjustment for mild impairment.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min).
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce dose by 50% or extend interval. Use with caution in mild impairment.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B: initiate at 15 mg once daily; do not increase dose. Use with caution.
Not recommended for children under 12 years. For adolescents 12-18 years, 1 tablet orally twice daily.
Safety and efficacy not established in pediatric patients under 12 years. For ages 12 and older, same as adult dosing.
Initiate at 1 tablet orally twice daily due to increased risk of anticholinergic effects and renal clearance decline. Monitor for confusion, urinary retention, and falls.
Initiate at 15 mg once daily. Due to higher incidence of anticholinergic effects and falls, monitor closely; consider lower doses in frail elderly.
None
None
Anticholinergic effects: confusion, hallucinations, urinary retention, blurred vision; caution in patients with glaucoma, prostatic hypertrophy, or myasthenia gravis; CYP2B6/CYP3A4 interactions; aspirin-related: increased bleeding risk, Reye's syndrome in children/viral illness, salicylate toxicity; avoid use with alcohol, other NSAIDs, or anticoagulants; use with caution in renal impairment, hepatic impairment, or peptic ulcer disease; may cause drowsiness or dizziness.
Abrupt discontinuation may precipitate withdrawal syndrome including hallucinations, seizures, autonomic instability.,May cause sedation, dizziness, and muscle weakness; caution with activities requiring alertness.,Use with caution in patients with impaired renal function due to reduced clearance.,May exacerbate seizures in patients with epilepsy.,Avoid concomitant use with other CNS depressants.
Hypersensitivity to orphenadrine, aspirin, or any component; patients with glaucoma (narrow-angle); gastrointestinal obstruction; achalasia; myasthenia gravis; severe renal or hepatic impairment; bleeding disorders; children or teenagers with viral infections (Reye's syndrome risk); concurrent use of anticholinergic agents; pregnancy (third trimester) due to premature closure of ductus arteriosus; severe hypertension or cardiovascular disease.
Hypersensitivity to amrix or baclofen.,Abrupt withdrawal is contraindicated; must be tapered.,Concomitant use with MAO inhibitors is contraindicated due to risk of hypertensive crisis.
Avoid alcohol. Take with food to minimize GI irritation. Caffeine content (30 mg per tablet) may cause jitteriness if combined with other caffeine sources. High-tyramine foods (aged cheese, cured meats) may increase pressor effect in susceptible individuals, though less common with this combination.
Avoid grapefruit and grapefruit juice during treatment as they may increase cyclobenzaprine levels. Taking AMRIX with or without food does not significantly affect absorption. Alcohol should be strictly avoided as it potentiates CNS depression.
First trimester: Avoid due to potential skeletal and visceral malformations (animal studies). Second/third trimester: Risk of premature closure of ductus arteriosus and oligohydramnios (NSAID component orphenadrine/paracetamol with NSAID? Note: Norgesic Forte contains orphenadrine, paracetamol, and caffeine; no NSAID clinically; teratogenicity primarily from orphenadrine anticholinergic effects). Limited human data; consider alternative.
Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacking. Use only if clearly needed. First trimester: no specific teratogenic effects documented; second and third trimesters: avoid near term due to potential neonatal effects (e.g., sedation, withdrawal).
Orphenadrine: excreted in breast milk in small amounts (M/P ratio unknown); potential anticholinergic effects in infant. Paracetamol: safe, low excretion (M/P ~1). Caffeine: moderate excretion (M/P ~0.5-1). Avoid use during breastfeeding due to lack of safety data for anticholinergic component.
Cyclobenzaprine is excreted into human milk in small amounts. M/P ratio: not established. Use with caution in nursing mothers; monitor infant for sedation, poor feeding, or hypotonia.
No specific pharmacokinetic data for dose adjustment in pregnancy. Use lowest effective dose, shortest duration. Caution: increased volume of distribution may not require dose increase due to risk of adverse effects. Avoid in third trimester due to potential premature ductus closure (though orphenadrine is not an NSAID; but anticholinergic effects may still pose risk).
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy; however, due to potential for increased clearance, lowest effective dose should be used. Avoid use during labor and delivery due to potential neonatal depression.
Norgesic Forte combines orphenadrine citrate (muscle relaxant) with aspirin and caffeine. Avoid in glaucoma, myasthenia gravis, and GI obstruction. Monitor for anticholinergic effects (dry mouth, blurred vision, urinary retention). Use with caution in elderly due to risk of confusion and falls. Not recommended for long-term use beyond 2-3 weeks.
AMRIX (cyclobenzaprine extended-release) should not be used longer than 2-3 weeks due to lack of evidence for efficacy in muscle spasm beyond that period. It has significant anticholinergic effects; avoid in patients with glaucoma, urinary retention, or those taking MAOIs. Do not crush or chew capsules; administer once daily at same time. Onset of action is delayed compared to immediate-release cyclobenzaprine.
Take with food or milk to reduce stomach upset.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause dizziness, drowsiness, or blurred vision.,Avoid alcohol and other CNS depressants.,Report severe stomach pain, black stools, or vision changes immediately.,Do not take more than prescribed; overdose can cause serious cardiac effects.
Take AMRIX exactly once daily at the same time each day; do not crush, chew, or open the capsule.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase the risk of severe drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how AMRIX affects you; it may cause drowsiness, dizziness, or blurred vision.,Contact your healthcare provider if you experience symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness, nausea, diarrhea).,Do not use AMRIX for longer than 2-3 weeks unless specifically directed by your doctor; prolonged use is not recommended.,Inform your doctor if you have a history of urinary retention, glaucoma, thyroid disorders, heart problems, or liver disease.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORGESIC FORTE vs AMRIX, answered by our medical review team.
NORGESIC FORTE is a Muscle Relaxant that works by Norgesic Forte is a combination of orphenadrine citrate and aspirin (acetylsalicylic acid). Orphenadrine is a centrally acting muscle relaxant with anticholinergic and antihistaminic properties; it acts via blockade of nicotinic acetylcholine receptors at the neuromuscular junction and centrally as a non-competitive antagonist at NMDA receptors, reducing hypertonicity and spasm. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.. AMRIX is a Muscle Relaxant that works by Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORGESIC FORTE and AMRIX depend on the specific clinical indication. These are both Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORGESIC FORTE is: 1 tablet orally 3 times daily. Each tablet contains orphenadrine citrate 100 mg and paracetamol 500 mg.. The standard adult dose of AMRIX is: 15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORGESIC FORTE and AMRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORGESIC FORTE is classified as Category C. First trimester: Avoid due to potential skeletal and visceral malformations (animal studies). Second/third trimester: Risk of premature closure of ductus arteriosus and oligohydram. AMRIX is classified as Category C. Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacki. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.